Item 7.01 - Regulation FD Disclosure.
On March 9, 2021, James C. Clemmer, President and Chief Executive Officer of
AngioDynamics, Inc. ("AngioDynamics"), and Stephen A. Trowbridge, Executive Vice
President and Chief Financial Officer of AngioDynamics, will present at the
Barclays Global Healthcare Conference. The presentation slides are furnished
herewith as Exhibit 99.1.
The presentation slides furnished pursuant to Item 7.01 of this Form 8-K
(including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
otherwise subject to the liabilities under that Section. Furthermore, the
presentation slides shall not be deemed to be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Exchange Act.
Forward-Looking Statements
This document and its attachments contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All statements
regarding AngioDynamics' expected future financial position, results of
operations, cash flows, business strategy, budgets, projected costs, capital
expenditures, products, competitive positions, growth opportunities, plans and
objectives of management for future operations, as well as statements that
include the words such as "expects," "reaffirms," "intends," "anticipates,"
"plans," "believes," "seeks," "estimates," "optimistic," or variations of such
words and similar expressions, are forward-looking statements. These
forward-looking statements are not guarantees of future performance and are
subject to risks and uncertainties. Investors are cautioned that actual events
or results may differ from AngioDynamics' expectations. Factors that may affect
the actual results achieved by AngioDynamics include, without limitation, the
scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to
develop its existing and new products, technological advances and patents
attained by competitors, infringement of AngioDynamics' technology or assertions
that AngioDynamics' technology infringes the technology of third parties, the
ability of AngioDynamics to effectively compete against competitors that have
substantially greater resources, future actions by the FDA or other regulatory
agencies, domestic and foreign health care reforms and government regulations,
results of pending or future clinical trials, overall economic conditions, the
results of on-going litigation, challenges with respect to third-party
distributors or joint venture partners or collaborators, the results of sales
efforts, the effects of product recalls and product liability claims, changes in
key personnel, the ability of AngioDynamics to execute on strategic initiatives,
the effects of economic, credit and capital market conditions, general market
conditions, market acceptance, foreign currency exchange rate fluctuations, the
effects on pricing from group purchasing organizations and competition, the
ability of AngioDynamics to integrate purchased businesses, as well as the risk
factors listed from time to time in AngioDynamics' SEC filings, including but
not limited to its Annual Report on Form 10-K for the year ended May 31, 2020
and its Quarterly Reports on Form 10-Q for the fiscal periods ended August 31,
2020 and November 30, 2020. AngioDynamics does not assume any obligation to
publicly update or revise any forward-looking statements for any reason.

--------------------------------------------------------------------------------




Item 9.01 - Financial Statements and Exhibits.
(d)   Exhibits.
Exhibit No.   Description

  99.1          Presentation slides for the Barclays Global Healthcare Conference,
              dated March 9, 2021

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses